Disclaimer: All content on this site is provided in good faith and for informational purposes only. Unless explicitly stated and sourced, all information should be considered alleged and unverified. We quote third parties and include archival material for informational and educational purposes, and do not endorse defamatory or harmful statements. For full details, visit our Disclaimer page.
No Trial Data, No Vax: FDA Demands Gold Standard Testing For Any New COVID-19 Vaccines
2025-05-20
154 words
1 min read
No Trial Data, No Vax: FDA Demands Gold Standard Testing For Any New COVID-19 Vaccines
The Food and Drug Administration (FDA) will not approve COVID-19 vaccines for many Americans absent trial data showing that the benefits outweigh the risks, top agency officials said on May 20.
“Moving forward, the FDA will adopt the following Covid-19 vaccination regulatory framework: On the basis of immunogenicity—proof that a vaccine can generate antibody titers in people—the FDA anticipates that it will be able to make favorable benefit–risk findings for adults over the age of 65 years and for all persons above the age of 6 months with one or more risk factors that put them at high risk for severe Covid-19 outcomes,” such as asthma or cancer, FDA Commissioner Dr. Marty Makary and Dr. Vinay Prasad, head of the FDA’s Center for Biologics Evaluation and Research, wrote in a New England Journal of Medicine article.
Source:
This article includes information sourced from third parties. Where sources are unavailable, such as broken or missing links, we were unable to directly verify the claims. Readers are encouraged to evaluate the information critically and seek additional verification where necessary.
Authored By TMB LLC
Our Mission is to bridge the gap between mainstream and independent news while offering transparent, honest, and reliable information.